The positive results from the OASIS 1 trial indicate that Novo Nordisk's oral semaglutide 50 mg has the potential to be a successful obesity treatment. The statistically significant weight loss compared to placebo demonstrates the drug's effectiveness. Regulatory approval in the US and EU in 2023 would open up new markets for the company, potentially increasing its revenue and positively impacting its stock price in the short term.